Phase 3 trial data for Covaxin released, shows 65% efficacy against Delta COVID variant

Bharat Biotech has released results from final analysis from Phase 3 trial for Covaxin COVID-19 vaccine. It said that the vaccine provides 65.2% protection against the Delta COVID-19 variant, which was first detected in India. The company further claimed that the vaccine demonstrates overall efficacy of 77.8% against symptomatic infection. Around 26,000 people had volunteered for the trial.